BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dmytriyeva O, Belmeguenai A, Bezin L, Soud K, Drucker Woldbye DP, Gøtzsche CR, Pankratova S. Short erythropoietin-derived peptide enhances memory, improves long-term potentiation, and counteracts amyloid beta–induced pathology. Neurobiology of Aging 2019;81:88-101. [DOI: 10.1016/j.neurobiolaging.2019.05.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Baerends E, Soud K, Folke J, Pedersen AK, Henmar S, Konrad L, Lycas MD, Mori Y, Pakkenberg B, Woldbye DPD, Dmytriyeva O, Pankratova S. Modeling the early stages of Alzheimer's disease by administering intracerebroventricular injections of human native Aβ oligomers to rats. Acta Neuropathol Commun 2022;10:113. [PMID: 35974377 DOI: 10.1186/s40478-022-01417-5] [Reference Citation Analysis]
2 Chiang MC, Nicol CJB. GSH-AuNP anti-oxidative stress, ER stress and mitochondrial dysfunction in amyloid-beta peptide-treated human neural stem cells. Free Radic Biol Med 2022:S0891-5849(22)00219-2. [PMID: 35660451 DOI: 10.1016/j.freeradbiomed.2022.05.025] [Reference Citation Analysis]
3 Cho B, Yoo SJ, Kim SY, Lee CH, Lee YI, Lee SR, Moon C. Second-generation non-hematopoietic erythropoietin-derived peptide for neuroprotection. Redox Biol 2021;49:102223. [PMID: 34953452 DOI: 10.1016/j.redox.2021.102223] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Nurmasitoh T, Sari DCR, Susilowati R. Toxic Substance-induced Hippocampal Neurodegeneration in Rodents as Model of Alzheimer’s Dementia. Open Access Maced J Med Sci 2021;9:523-533. [DOI: 10.3889/oamjms.2021.6984] [Reference Citation Analysis]
5 Newton SS, Sathyanesan M. Erythropoietin and Non-Erythropoietic Derivatives in Cognition. Front Pharmacol 2021;12:728725. [PMID: 34552490 DOI: 10.3389/fphar.2021.728725] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Jacobs RA, Aboouf MA, Koester-Hegmann C, Muttathukunnel P, Laouafa S, Arias-Reyes C, Thiersch M, Soliz J, Gassmann M, Schneider Gasser EM. Erythropoietin promotes hippocampal mitochondrial function and enhances cognition in mice. Commun Biol 2021;4:938. [PMID: 34354241 DOI: 10.1038/s42003-021-02465-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
7 Vittori DC, Chamorro ME, Hernández YV, Maltaneri RE, Nesse AB. Erythropoietin and derivatives: Potential beneficial effects on the brain. J Neurochem 2021. [PMID: 34278579 DOI: 10.1111/jnc.15475] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
8 Zhu L, Shi Y, Xiong Y, Ba L, Li Q, Qiu M, Zou Z, Peng G. Emerging self-assembling peptide nanomaterial for anti-cancer therapy. J Biomater Appl 2021;:8853282211027882. [PMID: 34180306 DOI: 10.1177/08853282211027882] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Bürgi M, Aparicio GI, Dorella A, Kratje R, Scorticati C, Oggero M. Novel erythropoietin-based therapeutic candidates with extra N-glycan sites that block hematopoiesis but preserve neuroplasticity. Biotechnol J 2021;16:e2000455. [PMID: 33471394 DOI: 10.1002/biot.202000455] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
10 Choi YB, Dunn-Meynell AA, Marchese M, Blumberg BM, Gaindh D, Dowling PC, Lu W. Erythropoietin-derived peptide treatment reduced neurological deficit and neuropathological changes in a mouse model of tauopathy. Alzheimers Res Ther 2021;13:32. [PMID: 33504364 DOI: 10.1186/s13195-020-00766-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Pekas NJ, Petersen JL, Sathyanesan M, Newton SS. Design and Development of a Behaviorally Active Recombinant Neurotrophic Factor. Drug Des Devel Ther 2020;14:5393-403. [PMID: 33304094 DOI: 10.2147/DDDT.S274308] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Perucca P, Tomson T, White HS. Progress report on new antiepileptic drugs: A summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). I. Drugs in preclinical and early clinical development. Epilepsia 2020;61:2340-64. [DOI: 10.1111/epi.16725] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
13 Ivanov I, Nikiforov A, Vengerovich N, Perelygin VV, Proshina Y. Pathogenic substantiation of application of erythropoietin modified forms and peptide analogues as cytotprotectors. Pharmacy Formulas 2020;2:70-81. [DOI: 10.17816/phf21382] [Reference Citation Analysis]